WHO = World Health Organization found no evidence to reduce mortality, etc., regarding treatment using "recoverer plasma" that administers blood components of people who have recovered from infection with the new coronavirus to patients. We have published guidelines that do not recommend administration to patients.
WHO analyzed a clinical trial conducted on 16,236 people around the world on "recovery plasma treatment" that administers plasma of people who have recovered from infection with the new coronavirus to patients, and on the 7th, a new treatment Guidelines have been published.
According to this, there was no evidence that administration of "Recovery Plasma" would reduce mortality or eliminate the need for a ventilator.
Nonetheless, WHO does not recommend administration to patients, as this treatment is expensive and time-consuming to manage the equipment.
"Recovery plasma treatment" for patients with the new corona has been studied in various countries since last year, and urgent use was permitted in the United States, but after that, research results have shown that it does not lead to a decrease in mortality rate. It was announced at.
Regarding the therapeutic drug for the new corona, WHO has developed steroids such as "antibody cocktail therapy" that administers two types of drugs to mildly ill patients at the same time, and "dexamethasone" for severely ill patients, and developed in Japan. It is recommended to administer "Actemra", a treatment for rheumatoid arthritis.